Dried Plasma Innovation Addresses Critical Global Need

First-in-Human Trial Demonstrates FrontlineODP™ Spray Dried Plasma Safety First-in-Human Trial Demonstrates FrontlineODP™ Spray Dried Plasma Safety Velico recently completed its first-in-human Phase Imulti-center clinical trial  of FrontlineODP™ Spray Dried Plasma in healthy volunteers. The  dose-escalation study with a   randomized, crossovercohort demonstrated the  safety of the spray dried plasma, with no serious adverse events or safety signals reported. "This trial marks the...

BEVERLY, Mass., 14/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Velico recently completed its first-in-human Phase I  of FrontlineODP™ Spray Dried Plasma in healthy volunteers. The    cohort demonstrated the  , with no serious adverse events or safety signals reported.

"This trial marks the beginning of a new era in plasma therapy," said , Chief Medical Officer at Velico. "A plasma product that's safe, portable, and transfusion-ready in just 2.5 minutes could transform how trauma is treated - both on the battlefield and in civilian emergencies."

The clinical success comes at a time when the - fewer than , and production is highly centralized in a few countries. This scarcity , particularly in the face of increasing .

It is produced through a decentralized model, ensuring accessibility where it's needed most. The product is , , and can be in emergencies.

These features would enable governments and healthcare systems to build , improving emergency readiness across both civilian and military sectors.

"Current limited supply of dried plasma requires a new solution," said , CEO of Velico. "This is about . Nations need the ability to invest in domestic capacity now, or they may face being unprepared when the next crisis hits."

Velico's clinical trial findings will be featured as a at the this October — a significant acknowledgment of the FrontlineODP™ Spray Dried Plasma's relevance to the future of transfusion medicine and trauma care.

CAUTION: Investigational device. Limited by Federal (or US) law to investigational use.
The FrontlineODP™ Spray Dried Plasma System has not received FDA or EU approval for any indication. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability.

Velico's development program has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00059.

Velico is a private US medical technology company, committed to the mission of eliminating preventable death from bleeding. Headquartered in Beverly, Massachusetts , USA. Velico personnel have substantial expertise and experience in transfusion medicine and medical device development. In support of its mission, Velico is developing partnerships with civilian, government and military blood center leadership, trauma surgeons, emergency medical physicians, military medics and first responders worldwide.
For more information visit www.veli.co

Photo - https://mma.prnewswire.com/media/2750857/Velico_Medical_Lady_ODP.jpg

Logo - https://mma.prnewswire.com/media/2152986/Velico_Medical_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dried-plasma-innovation-addresses-critical-global-need-302530492.html